Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$136.06 USD
+1.81 (1.35%)
Updated Oct 17, 2025 04:00 PM ET
After-Market: $136.03 -0.03 (-0.02%) 6:54 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
JAZZ 136.06 +1.81(1.35%)
Will JAZZ be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JAZZ
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why JAZZ Stock Is an Unconventional Cannabis Investment
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
Other News for JAZZ
3 Small Cap Stocks To Play As The Bantamweights Break Out On Wall Street
First Week of June 2026 Options Trading For Jazz Pharmaceuticals (JAZZ)
JAZZ falls 1.14% on October 16, leaving the technical picture intact
Jazz Pharmaceuticals Completes Study on Promising HER2 Cancer Treatment
Is JAZZ positioned for a breakout? 20 Day Moving Average Support shows up after climbing 1.49%